Generic Name and Formulations:
Trivalent, inactivated, adjuvanted (MF59C.1) influenza vaccine (virus types A and B); contains a total of at least 45mcg of hemagglutinin per 0.5mL dose; formulation changes annually; susp for IM inj; may contain trace amounts of neomycin, kanamycin, barium, egg proteins, formaldehyde; preservative-free.
Indications for FLUAD:
Influenza immunization for patients ≥65yrs of age.
<65yrs: not established. ≥65yrs: 0.5mL IM inj once in the deltoid; 1 dose per year.
Allergy to egg protein. Life-threatening reaction to any previous flu vaccine.
Use current formulation only. Have appropriate medical treatment and supervision readily available. Guillain-Barre syndrome within 6 weeks of previous flu vaccine. Immunosuppressed. Pregnancy (Cat.B).
Concomitant vaccines: insufficient data (see full labeling). Immunosuppressants (eg, corticosteroids): may get suboptimal response.
Local reactions (eg, pain, tenderness), myalgia, headache, fatigue; syncope.
Single-dose prefilled syringe (0.5mL)—1, 10 (without needles)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC